

RPG Life offers drug to delay dialysis in kidney patient

PRESS TRUST OF INDIA

Mumbai

RPG Group's pharma arm on Tuesday launched an indigenously developed drug, which it claimed, would delay the renal replacement therapy (dialysis) among chronic kidney failure patients.

'Ketoanalogue' (generic name of the brand Alfalog), has been developed, manufactured by RPG Life Sciences, the pharma and biotech arm of the multi-billion RPG Group. When administered in the early stages of chronic kidney failure patients, Ketoanalogue would delay the stage of reaching the process of dialysis at least by two to three years, RPG Life Sciences managing director Ajit Singh Chouhan said.

This is the first indigenously researched, developed and manufactured Ketoanalogue, he said, adding so far India has been importing the medicine from Fresenius Kabi, the original inventor.

"The product is a complex mix of 10 active ingredients. The technological breakthrough allows the product to remain stable and have better dissolution," he said, adding it has received FDA approval. "The product, being very sensitive to temperature and moisture, needs to have high stability," he explained.